Hamlet BioPharma Schedules Monthly Digital Investor Meeting
Hamlet BioPharma has scheduled its monthly digital investor meeting for September 23, 2026. The session will provide investors with a regular update on the company's activities.
Lund-based Hamlet BioPharma will hold its monthly digital investor meeting on Wednesday, September 23, 2026. The meeting is set to commence at 12:00 PM and aims to provide stakeholders with a regular update on the company's ongoing developments.
Participation in the meeting will be conducted online via Zoom. The company has provided the necessary participation link and access details in its press release.
Hamlet BioPharma is focused on developing treatments for cancer and infectious diseases. Recent company announcements include findings on the metabolic health benefits of its BAMLET treatment and its potential for commercialization through nutritional pathways. Additionally, the company recently completed patient enrollment for its Phase III clinical trial in bladder cancer.
Further information regarding the meeting and the company's operations is available through Chief Financial Officer Jakob Testad and Chief Executive Officer Catharina Svanborg.